Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2018/03/012393
CTRI/2018/03/012393
Completed
未知

An open-label, single centre, pilot clinical study to evaluate the effect of CurQfen on brain function in Middle aged to Elderly population by Quantitative EEG analysis and cognitive assessment tests.

Akay Flavours and Aromatics Private Limited0 sites6 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Akay Flavours and Aromatics Private Limited
Enrollment
6
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 29, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Akay Flavours and Aromatics Private Limited

Eligibility Criteria

Inclusion Criteria

  • •1\)Age 35\-65 Years ( Both Inclusive)
  • •2\)Male and Female Subjects
  • •3\)Subjects in general good health.
  • •4\)Subjects with a MMSE score between 25 â?? 30

Exclusion Criteria

  • •EXCLUSION CRITERIA
  • •1\)Subjects with a education qualification less than higher secondary level
  • •2\)Subjects who are not familiar with computer/internet use.
  • •3\)Subject with dementia/related memory loss illness
  • •4\)Subjects diagnosed with learning difficulty such as dyslexia or dyspraxia
  • •5\)Suffering from any form of clinically diagnosed disease, including:
  • •oMajor mental illness (current or previous episode with hospitalization)
  • •oChronic fatigue syndrome
  • •oLiver disease
  • •oDiabetes mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The effect of Rhodiola rosea Extract WS 1375 on attention and mental resource allocatio
ISRCTN29449049Dr. Willmar Schwabe GmbH & Co. KG (Germany)50
Active, not recruiting
Not Applicable
Medical research trial for testing drug treatment of alpha-Mannosidosisalpha-MannosidosisMedDRA version: 17.1Level: LLTClassification code 10032658Term: Other specified disorders of carbohydrate transport and metabolismSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2014-003950-15-DKZymenex A/S
Completed
Not Applicable
A single centre, open label trial investigating the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjectsgroeihormoondeficientiegrowth hormone deficiency
NL-OMON42854ovo Nordisk A/S7
Active, not recruiting
Phase 1
A study to investigate a new medication, NI-0501, in children with the disease systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH)
EUCTR2016-004223-23-FRovimmune SA10
Active, not recruiting
Phase 1
A study to investigate a new medication, NI-0501, in children with the disease systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH)Macrophage activation syndrome / Secondary hemophagocytic lymphohistiocytosis (MAS/sHLH) in patients with Systemic Juvenile Idiopathic Arthritis (sJIA)MedDRA version: 21.1Level: LLTClassification code 10053867Term: Macrophage activation syndromeSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2016-004223-23-NLovimmune SA10